AD

Award Number: DAMD17-98-1-8016

TITLE: Preliminary Investigation of the Role of Cellular

Immunity in Estrous Cycle Modulation of Post-Resection

Breast Cancer Spread

PRINCIPAL INVESTIGATOR: William J. M. Hrushesky, M.D.

CONTRACTING ORGANIZATION: Dorn Research Institute, Incorporated

Columbia, South Carolina 29209

REPORT DATE: December 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030701 143

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		3. REPORT TYPE AND I			
4. TITLE AND SUBTITLE	December 2002		r 99 - 30 Nov 02)		
Preliminary Investigation of the Role of Cellular			5. FUNDING NUMBERS DAMD17-98-1-8016		
Immunity in Estrous	DAMDI 1-98	3-1-8016			
Resection Breast Ca	DI POSL-				
6. AUTHOR(S):					
William J. M. Hrushesky, M.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			8. PERFORMING ORGANIZATION		
7. FERFORMING ORGANIZATION NAMICIS) AND ADDRESS(ES)			REPORT NUMBER		
Dorn Research Insti	tute, Incorporated				
Columbia, South Car	olina 29209				
E-Mail: willaim.hrushesky@med.va.go	у				
9. SPONSORING / MONITORING AC	SENCY NAME(S) AND ADDRESS(ES)	10. SPONSORIN	G / MONITORING	
U.S. Army Medical Research and	Material Commend		AGENCY RE	PORT NUMBER	
Fort Detrick, Maryland 21702-50					
11. SUPPLEMENTARY NOTES					
11. SUFFLEWENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE	
Approved for Public Rel	lease. Distribution Unl	imited	Į.		
Approved for Public Rel	lease; Distribution Unl	imited			
Approved for Public Rel	lease; Distribution Unl	imited			
13. Abstract (Maximum 200 Words)	(abstract should contain no propriet	ary or confidential inform	ation)		
13. Abstract (Maximum 200 Words) It is hypothesized that	(abstract should contain no propriet The short term object	ary or confidential informatives of doing the	his proposa	l are to better	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st	(abstract should contain no propriet The short term object ceroids and which cells	ary or confidential informatives of doing the large instance of the large functions of the	his proposa tions contr	al are to better	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spreatestable hypotheses for	(abstract should contain no propriet The short term object teroids and which cellud ad. The long term goal or "neoadjuvant" hormona	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spreatestable hypotheses for	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer sprea testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which cellud. The long term goal "neoadjuvant" hormona of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which celludd. The long term goal "neoadjuvant" hormone of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spread testable hypotheses for at or around the time of	(abstract should contain no propriet The short term object ceroids and which celludd. The long term goal "neoadjuvant" hormone of a cancer resection,	ary or confidential informatives of doing the later immune functions to use this al/immunological	his proposa tions contr understand therapies,	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer sprea testable hypotheses for at or around the time of metastatic spread of th	(abstract should contain no propriet The short term object ceroids and which cells ad. The long term goal r "neoadjuvant" hormona of a cancer resection, ne resected cancer.	ary or confidential informatives of doing the lar immune function is to use this al/immunological might result in	his proposa tions contr understand therapies, diminishin	al are to better ol post resection ling to develop which when given	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer sprea testable hypotheses for at or around the time of metastatic spread of th	(abstract should contain no propriet The short term object ceroids and which cells ad. The long term goal r "neoadjuvant" hormona of a cancer resection, ne resected cancer.	ary or confidential informatives of doing the lar immune function is to use this al/immunological might result in	his proposa tions contr understand therapies, diminishin	al are to better ol post resection ling to develop which when given ag the subsequent	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer sprea testable hypotheses for at or around the time of metastatic spread of th	(abstract should contain no propriet The short term object ceroids and which cells ad. The long term goal r "neoadjuvant" hormona of a cancer resection, ne resected cancer.	ary or confidential informatives of doing the lar immune function is to use this al/immunological might result in	his proposa tions contr understand therapies, diminishin	al are to better ol post resection ling to develop which when given ag the subsequent	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer sprea testable hypotheses for at or around the time of metastatic spread of th 14. SUBJECT TERMS surgery, neoplasm, estrou	(abstract should contain no propriet The short term object ceroids and which cells ad. The long term goal r "neoadjuvant" hormone of a cancer resection, ne resected cancer.	ary or confidential informatives of doing the clar immune function is to use this al/immunological might result in a cy, chronobiology	his proposa tions contr understand therapies, diminishin	al are to better ol post resection ling to develop which when given ag the subsequent	
13. Abstract (Maximum 200 Words) It is hypothesized that understand which sex st metastatic cancer spreatestable hypotheses for at or around the time of metastatic spread of the metastatic spread	(abstract should contain no propriet The short term object ceroids and which cells ad. The long term goal r "neoadjuvant" hormone of a cancer resection, ne resected cancer.	ary or confidential informatives of doing the clar immune function is to use this al/immunological might result in	his proposations contrunderstand therapies, diminishin	al are to better rol post resection ling to develop which when given ag the subsequent 15. NUMBER OF PAGES 4 16. PRICE CODE	

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

Table of Contents

Cover	
SF 298	2
Introduction	4
Body	4
Key Research Accomplishments	4
Reportable Outcomes	4
Conclusions	4
References	4
Appendices	4

Annual Report (April 19, 1999 – November 30, 2002) William J.M. Hrushesky, M.D. DAMD17-98-1-8016 December 30, 2002

Introduction: This grant was awarded to the Albany Research Institute at Stratton Veterans Affairs Medical Center, Albany, New York (WJM Hrushesky, PI) on April 20, 1998. The PI relocated to the Wm. Jennings Bryan Dorn VA Medical Center in Columbia South Carolina in the summer of 2000. Since that time, the PI and the new Awardee Institution, the Dorn Research Institute, Inc. have been in the process of transferring the award to the DRI. For a variety of reasons, this process has taken a great deal of time. The modified assistance agreement (DAMD17-98-1-8016, Modification No. P00001) was executed by all parties on August 19, 2002 with a modified performance period (20 April 98 – 3 Aug 04). The transfer of funding was not completed until the Dorn Research Institute deposited the check dated November 20, 2002 on December 23, 2002. As such, the proposed research was not re-initiated during this reporting period and there are not results or conclusions to report. The institution and principal investigator are poised to begin experiments in early January 2003 and finalize experimentation during the approved period.

Body: N/A (see above).

Key Research Accomplishments: None this reporting period.

Reportable Outcomes: None to date.

Conclusions: None to date.

References: None.

Appendices: None.